Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial

Keyphrases

• Amyotrophic Lateral Sclerosis 100%
• Platform Trials 100%
• Placebo 50%
• ALSFRS-R 41%
• Disease Incidence 33%
• Rate Ratio 33%
• Domain Scores 16%
• Bulbar 16%
• 1 Receptor 16%
• Bulbar Dysfunction 16%
• Disease Progression 8%
• Placebo Groups 8%
• Adverse Events 8%
• Great Changes 8%
• Receptor Agonist 8%
• No Significant Difference 8%
• Twice Daily 8%
• Fatal Infection 8%
• Disease Severity 8%
• 2-component 8%
• Randomized Double-blind 8%
• Shared Parameter Model 8%
• Trial Registration 8%
• Time Since Death 8%
• Decline Rate 8%
• Assisted Ventilation 8%
• Credible Interval 8%
• Revised Amyotrophic Lateral Sclerosis Functional Rating Scale 8%
• Slow Vital Capacity 8%
• Efficacy Analysis 8%
• Muscular Weakness 8%
• Efficacy Outcomes 8%
• Infection Probability 8%
• Change from Baseline 8%
• Amyotrophic Lateral Sclerosis Disease 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Amyotrophic Lateral Sclerosis 100%
• Placebo 58%
• Diseases 50%
• Receptor Agonist 8%
• Receptor 8%
• Disease Exacerbation 8%
• Adverse Event 8%
• Muscle Weakness 8%
• Disease Severity 8%

Medicine and Dentistry

• Pridopidine 100%
• Bulbar Palsy 16%
• Slow Vital Capacity 8%